



NEWPORT GENERIC DEALS MODULE

INTELLIGENCE AT YOUR FINGERTIP FOR YOUR NEXT DEAL

HOW TO SUBSCRIBE

The *Newport Generic Deals Module* is an optional subscription module that may be added on a per-seat basis to *Newport Premium™*, *Newport Global™*, and *Newport Sourcing™* product configurations for an additional annual charge. A subscription to a base system is required before purchasing this module. To get a quotation, contact your account manager or visit science.thomsonreuters.com/info/sales

WHAT GENERIC DEALS CAN HELP YOU DO

- Seek out partners and acquisition targets
- Anticipate moves by your competitors
- Improve and streamline your partner selection process and sourcing decisions
- Analyze deal making trends over the past 10 years and company growth strategies
- Evaluate potential acquisition targets

GAIN A COMPETITIVE EDGE BY HAVING ALL THE FACTS AT HAND

The *Newport Generic Deals Module* provides you with all the facts you need to make a deal, choose a partner, scout the competition, or look for your next acquisition.

Seamlessly integrated into *Newport Sourcing™*, *Newport Global™* and *Newport Premium™*, *Generic Deals* contains detailed intelligence from Thomson Reuters on thousands of merger and acquisition, development, supply, manufacturing, joint venture, patent settlement, and authorized generic deals involving generic companies worldwide since 1999.

For each deal, and where applicable, you can explore the parties involved, their geographic location, announcement and transaction dates, source attribution, dollar value, deal financials, and percentage stake, the deal type and status, and a summary description.

You can set email alerts to be sent to you automatically for new or changed deals associated with any corporate group in the database.

A new focused search enables you to conduct comprehensive analysis of global generic deal-making activity. Email alerts advise you of the latest changes to deals being pursued and closed by the generic industry worldwide.

HOW YOU BENEFIT

- Monthly intelligence updates
- Simple web-based interface
- Comprehensive training and technical support
- Integrated on-line help
- Zero cost deployment
- Secure, confidential hosted access

GENERIC DEALS HELPS YOUR STRATEGIC PLANNING TEAM TO:

- Improve, inform and streamline your partner selection process
- Analyze deal making trends over the past 10 years and company growth strategies
- Evaluate potential acquisition targets
- Anticipate moves by your competitors

GENERIC DEALS HELPS YOUR BUSINESS DEVELOPMENT TEAM TO:

- Profile partners for acquisition, alliances, licensing, or supply and manufacturing deals
- Improve your product selection process and sourcing decisions

GENERIC DEALS ALSO AIDS COMPANY AND PATENT INTELLIGENCE

Generic Deals can help your company intelligence team to monitor deal-making activity by hundreds of companies. It can also help your product intelligence team to track and monitor deal-making around products of interest.

IP & SCIENCE REGIONAL OFFICES

North America

Philadelphia +1 855 260 5607
+1 215 386 0100

Latin America

+55 11 8370 9845

Europe, Middle East and Africa

London +0800 145 6412

Asia Pacific

Singapore +65 6775 5088
Tokyo +81 3 5218 6500

For a complete office list visit:
ip-science.thomsonreuters.com/contact

PH0906130e

Copyright © 2012 Thomson Reuters

| Acquirer/Principal Company | Country | Target/Partner Company | Country | Deal Type | Status |
|-------------------------------|-------------|--|-------------|-----------|-------------|
| Novartis AG | Switzerland | Hexal AG | Germany | MA | Completed |
| Novartis AG | Switzerland | Eon Labs Inc | US | MA | Completed |
| Novartis AG | Switzerland | Eon Labs Inc | US | MA | Completed |
| Novartis AG | Switzerland | Bristol-Myers Squibb Co-US Consumer Medicines Business | US | MA | Completed |
| Novartis Animal Health US Inc | US | Boehringer Ingelheim Vetmedica-Denagard Product Line | US | MA | Completed |
| Sandoz Farmaceutica Lda | Portugal | Boral-Prodacos Farmaceuticos SA | Portugal | MA | Completed |
| Novartis AG | Switzerland | Chiron Corp | US | MA | Completed |
| Novartis Pharma AG | Switzerland | NovTec Pharma Plc | UK | MA | Uncondition |
| Novartis Animal Health KK | Japan | Lifetech Animal Health Co Ltd | Japan | MA | Completed |
| Novartis AG | Switzerland | Thommen Medical AG | Switzerland | MA | Completed |
| Novartis AG | Switzerland | Intercell AG | Austria | MA | Completed |
| Novartis AG | Switzerland | Alicon Inc | US | MA | Completed |

New Deals pages for corporate groups display mergers and acquisitions, manufacturing and marketing alliances, litigation settlements, and other deals from the past 10 years.

| Deals Detail | |
|--|---|
| Acquirer/Principal Company Name | Actavis Group HF |
| Acquirer/Principal Company Country | Iceland |
| Target/Partner Company Name | Endo Pharmaceuticals Holdings Inc |
| Target/Partner Company Country | Iceland |
| Date Announced | 20 Feb 2009 |
| Date Effective | |
| Date Terminated | Status |
| Value (\$M) | Percentage Stake |
| Type | Patent Litigation Settlement |
| Products | oxymorphone hydrochloride |
| Summary | |
| In February 2009, Actavis entered into a litigation settlement agreement with Endo Pharmaceuticals and Penwest Pharmaceutical regarding the product (oxymorphone hydrochloride) Extended Release Tablets OI. | |

Deal detail pages highlight the involved parties, dates, and values, and provide a short synopsis of the deal.



THOMSON REUTERS™